Pharmaceutical company Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals inc. had obtained final approval from US FDA for its Lamivudine and Zidovudine tablets, 150mg/ 300mg.
The Mumbai-based company said it already commenced shipping the product.
Lupin's Lamivudine and Zidovudine tablets are the AB-rated generic equivalent of Viiv Healthcare's Combivir tablets, 150mg/300mg.
Lamivudine Zidovudine is a combination of two nucleoside analogue reverse transcriptase inhibitors and is indicted in combination with other antiretroviral agents for the treatment of HIV-1 infection.
As per IMS Health sales data, Combivir tablets had a sales of around $275 million in the US for the twelve months ended December 2011.
At the BSE, Lupin shares are currently trading at Rs.547.00, up 1.75 percent from the previous close.
For comments and feedback: editorial@rttnews.com